This result was somewhat surprising, given previous reports suggesting that CCND1 amplification is one of the cardinal features of aggressive ER+ breast cancers, that the expression of the CCND1 gene is induced by estrogens, and that its amplification affects clinical response to tamoxifen. This evidence concerns the gene CCND1 and breast carcinoma.